Objective:

The article examines the objective, findings, and clinical context described in Baptist Health Oncologist Rohan Garje Recognized for National Leadership in Cancer Treatment Guidelines.

Approach:

• Prostate cancer guidelines: Garje has chaired ASCO’s metastatic prostate cancer guideline development group since 2022. He led updates issued in 2022 and 2025; the 2025 guideline, published in the Journal of Clinical Oncology, addresses systemic therapy for metastatic castration-resistan…
• Maintaining and expanding guidance: He has advised ASCO committees on its living guideline process and contributed to guidance on mismatch repair and microsatellite instability testing, as well as reviews concerning other cancers and genomic testing.
• Professional service: Garje served on ASCO’s Trainee & Early Career Advisory Group from June 2021 to June 2023 and has served on its Genitourinary Cancer Guideline Advisory Group since June 2023.

Key Findings:

• ASCO issued major metastatic prostate cancer guideline updates in 2022 and 2025 under Garje’s leadership.
• Garje coauthored a 2026 JCO Oncology Practice article discussing updated recommendations.
• In July 2026, Garje received the FASCO designation for sustained volunteer service; formal recognition is expected at ASCO’s 2027 Annual Meeting.

Interpretation:

The article describes Garje’s national guideline work and broader volunteer contributions to ASCO as the basis for his FASCO recognition.

Limitations:

• The context does not provide clinical trial results or detailed treatment recommendations from the guidelines.
• No source URL was provided.

Conclusion:

Garje’s ASCO service includes leadership in metastatic prostate cancer guidance, work to keep recommendations current, and contributions to other guideline and professional development initiatives.